So, the natural question for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's ...

At the ASCO 2024 conference, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) reported promising results for CRB-701, showing an Overall Response Rate (ORR) of 44% in metastatic urothelial ...

Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.26 misses by $0.06. Revenue of $1.09M (+36.3% Y/Y) misses by... BySeeking Alpha • Nov 08, 2018 Corbus Pharma's lenabasum shows positive ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Corbus Pharmaceuticals Holdings Inc. closed 90.26% below its 52-week high of $61.90, which the company achieved on July 31st.

So, the natural question for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's ...